• Current Issue:
    5articles Vol.5(2024) , Issue 6
    Sort by
    Latest
    Open Access
    Perspective
    The promises and perils of circulating tumor DNA for monitoring immunotherapy response in non-small cell lung cancer
    There has been a rapid expansion of immunotherapy options for non-small cell lung cancer (NSCLC) over the past two decades, particularly with the advent of immune checkpoint inhibitors. Despite the  [...] Read more.
    Brandon Joseph Hebert, James Bradley
    Published: November 26, 2024 Explor Target Antitumor Ther. 2024;5:1365–1372
    DOI: https://doi.org/10.37349/etat.2024.00280
    This article belongs to the special issue Immunotherapy Strategies for Non-small Cell Lung Cancer
    View:221
    Download:15
    Times Cited: 0
    Open Access
    Review
    Targeted therapies and molecular targets in the therapeutic landscape of advanced urothelial carcinoma: state of the art and future perspectives
    Advanced urothelial carcinoma (aUC) has a dismal prognosis, with a 5-year survival rate of approximately 10%. Platinum-based chemotherapy has been the backbone of the first-line treatment of aUC for [...] Read more.
    Irene Testi ... Ursula Vogl
    Published: November 21, 2024 Explor Target Antitumor Ther. 2024;5:1326–1364
    DOI: https://doi.org/10.37349/etat.2024.00279
    This article belongs to the special issue Emerging Molecular Targets and Therapies of Genitourinary Tumors
    View:279
    Download:20
    Times Cited: 0
    Open Access
    Editorial
    Predictive and prognostic biomarkers in cancer: towards the precision medicine era
    Stefano Marletta ... Luca Falzone
    Published: November 20, 2024 Explor Target Antitumor Ther. 2024;5:1321–1325
    DOI: https://doi.org/10.37349/etat.2024.00278
    This article belongs to the special issue Predictive and Prognostic Biomarkers in Cancer: Towards the Precision Medicine Era
    View:157
    Download:10
    Times Cited: 0
    Open Access
    Review
    Addressing the unmet need in NSCLC progression with advances in second-line therapeutics
    Lung cancer is the leading cause of cancer mortality globally, with non-small cell lung cancer (NSCLC) accounting for 85% of cases. Despite advancements in first-line treatments such as immunotherap [...] Read more.
    Kinsley Wang ... Robert Hsu
    Published: November 1, 2024 Explor Target Antitumor Ther. 2024;5:1297–1320
    DOI: https://doi.org/10.37349/etat.2024.00277
    This article belongs to the special issue Immunotherapy Strategies for Non-small Cell Lung Cancer
    View:378
    Download:25
    Times Cited: 0
    Open Access
    Short Communication
    Preliminary evaluation of FAPI-04-PET/CT for differentiating recurrence and post-treatment changes in high-grade gliomas
    Fibroblast-activated protein (FAP) expression in glial cells is attributed to FAP-positive foci on tumor vessels and neoplastic cells. Preclinical and pilot studies have shown FAP expression in high [...] Read more.
    Indraja D. Dev ... Archi Agrawal
    Published: October 31, 2024 Explor Target Antitumor Ther. 2024;5:1289–1296
    DOI: https://doi.org/10.37349/etat.2024.00276
    View:267
    Download:24
    Times Cited: 0